title: Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians.
abstract: We hypothesized that common genomic variants would be associated with variation in lipoprotein phenotypes in young subjects. We determined genotypes of FABP2, PON, APOC3, and APOE in 188 aboriginal Canadians, aged 9 to 17 years. We found that 13 of 32 possible genotype-phenotype associations were significant: (1) the FABP2 codon 54 genotype was associated with variation in plasma triglycerides (P = .045); (2) the PON codon 192 genotype was associated with variation in plasma total and LDL cholesterol and apoB (P = .0099, P = .0088, and P = .016, respectively); (3) the APOC3 insulin-response-element genotype was associated with variation in plasma triglycerides, HDL cholesterol, apoA-I, the total cholesterol to HDL cholesterol ratio, and the apoB to apoA-I ratio (P = .0014, P = .0069, P = .045, P = .0021, and P = .0081, respectively); and (4) the APOE restriction isotype was associated with variation in plasma LDL cholesterol, apoB, the total cholesterol to HDL cholesterol ratio, and the apoB to apoA-I ratio (P = .025, P = .034, P = .045, and P = .047, respectively). The average young age and relative absence of age-dependent secondary environmental factors could have eased the identification of small genetic effects on lipoprotein phenotypes in this study sample.
authors.affiliation: Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada. robert.hegele@utoronto.ca
authors.forename: R A
authors.initials: RA
authors.lastname: Hegele
authors.forename: P W
authors.initials: PW
authors.lastname: Connelly
authors.forename: A J
authors.initials: AJ
authors.lastname: Hanley
authors.forename: F
authors.initials: F
authors.lastname: Sun
authors.forename: S B
authors.initials: SB
authors.lastname: Harris
authors.forename: B
authors.initials: B
authors.lastname: Zinman
mesh_terms: D000293:Adolescent; D000483:Alleles; D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics*; D043303:Aryldialkylphosphatase; D002170:Canada; D002352:Carrier Proteins / Q000235:genetics*; D002648:Child; D004950:Esterases / Q000235:genetics*; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007198:Indians, North American / Q000235:genetics*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D018996:Myelin P2 Protein / Q000235:genetics*; D009363:Neoplasm Proteins; D010641:Phenotype; D025521:Tumor Suppressor Proteins
chemical_list: D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D002352:Carrier Proteins; C493404:FABP2 protein, human; C107608:FABP7 protein, human; C493405:Fabp2 protein, mouse; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D008074:Lipoproteins; D018996:Myelin P2 Protein; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins; D004950:Esterases; D043303:Aryldialkylphosphatase